Urinary CD14 as a potential biomarker for benign prostatic hyperplasia - discovery by combining MALDI-TOF-based biostatistics and ESI-MS/MS-based stable-isotope labeling

Proteomics - Clinical Applications

Volumn 5, Issue 3-4, 2011, Pages 121-132

  Cheng, Hong Lin ^a   Huang, Hung Jen ^b   Ou, Bing Yuan ^b   Chow, Nan Haw ^b   Chen, Yen Wen ^c   Tzai, Tzong Shin ^a   Wu, Chin Jen ^b   Chen, Shu Hui ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CENTRAL UNIVERSITY   (Taiwan)

Author keywords

Benign prostatic hyperplasia; Biomarker; CD14

Indexed keywords

ALPHA AMYLASE PANCREAS ISOENZYME; BIOLOGICAL MARKER; CD14 ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; PROTEOMICS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; URINALYSIS; VALIDATION STUDY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD14; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; ISOTOPE LABELING; MALE; MIDDLE AGED; PANCREATIC ALPHA-AMYLASES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 79953114926     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000011     Document Type: Article

References (28)

1. Marks, L. S., Roehrborn, C. G., Andriole, G. L., Prevention of benign prostatic hyperplasia disease. J. Urol. 2006, 176, 1299-1306.
2. Marks, L. S., Treatment of men with minimally symptomatic benign prostatic hyperplasia - PRO: the argument in favor. Urology 2003, 62, 781-783.
3. Kaplan, S. A., Medical therapy for asymptomatic men with benign prostatic hyperplasia: primum non nocere. Urology 2003, 62, 784-785.
4. Hoom, E. J., Pisitkun, T., Zietse, R., Gross, P. et al., Prospects for urinary proteomics: exosomes as a source of urinary biomarkers. Nephrology (Carlton) 2005, 10, 283-290.
5. Pisitkun, T., Shen, R. F., Knepper, M. A., Identification and proteomic profiling of exosomes in human urine. Proc. Natl. Acad. Sci. USA 2004, 101, 13368-13373.
6. Spahr, C. S., Davis, M. T., McGinley, M. D., Robinson, J. H. et al., Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. 1. Profiling an unfractionated tryptic digest. Proteomics 2001, 1, 93-107.
7. Pang, J. X., Ginanni, N., Dongre, A. R., Hefta, S. A., Opitek, G. J., Biomarker discovery in urine by proteomics. J. Proteome Res. 2002, 1, 161-169.
8. Thongboonkerd, V., McLeish, K. R., Arthur, J. M., Klein, J. B., Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int. 2002, 62, 1461-1469.
9. Pieper, R., Gatlin, C. L., McGrath, A. M., Makusky, A. J. et al., Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield or nearly 1400 distinct protein spots. Proteomics 2004, 4, 1159-1174.
10. Oh, J., Pyo, J. H., Jo, E. H., Hwang, S. I. et al., Establishment of a near-standard two-dimensional human urine proteomic map. Proteomics 2004, 4, 3485-3497.
11. Smith, G., Barratt, D., Rowlinson, R., Nickson, J., Tonge, R., Development of a high-throughput method for preparing human urine for two-dimensional electrophoresis. Proteomics 2005, 5, 2315-2318.
12. Sun, W., Li, F., Wu, S., Wang, X. et al., Human urine proteome analysis by three separation approaches. Proteomics 2005, 5, 4994-5001.
13. Castagna, A., Cecconi, D., Senneis, L., Rappsilber, J. et al., Exploring the hidden human urinary proteome via ligand library beads. J. Proteome Res. 2005, 4, 1917-1930.
14. Jurgens, M., Appel, A., Heine, G., Neitz, S. et al., Towards characterization of the human urinary peptidome. Comb. Chem. High Throughput Screen. 2005, 8, 757-765.
15. Wang, L., Li, F., Sun, W., Wu, S. et al., Concanavalin A-captured glycoproteins in healthy human urine. Mol. Cell. Proteomics 2006, 5, 560-562.
16. Swets, J. A., Measuring the accuracy of diagnostic systems. Science 1988, 240, 1285-1293.
17. Unwin, R. D., Harnden, P., Pappin, D., Rahman, D. et al., Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 2003, 3, 45-55.
18. Ketterlinus, R., Hsieh, S. Y., Teng, S. H., Lee, H., Pusch, W., Fishing for biomarkers: analyzing mass spectrometry data with the new ClinProTools software. Biotechniques 2005, 37-40.
19. Aebersold, R., Tao, W. A., Advances in quantitative proteomics via stable isotope tagging and mass spectrometry. Curr. Opin. Biotechnol. 2003, 14, 110-118.
20. Ono, M., Shitashige, M., Honda, K., Isobe, T. et al., Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Mol. Cell. Proteomics 2006, 5, 1338-1347.
21. Hsu, J.-L., Huang, S.-Y., Chow, N.-H., Chen, S.-H., Stable-isotope dimethyl labeling for quantitative proteomics. Anal. Chem. 2003, 75, 6843-6852.
22. 1 ion as a mass tag for peptide sequencing using dimethyl labeling. J. Proteome Res. 2005, 4, 101-108.
23. Forootan, S. S., Foster, C. S., Aachi, V. R., Adamson, J. et al., Prognostic significance of osteopontin expression in human prostate cancer. Int. J. Cancer 2006, 118, 2255-2261.
24. Thompson, I. M., Pauler, P. J., Goodman, C. M., Tangen, M. S. et al., Prevalence of prostate cancer among men with a prostate-specific antigen level
25. M'Koma, A. E., Blum, D. L., Norris, J. L., Koyama, T. et al., Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. Biochem. Biophys. Res. Commun. 2007, 353, 829-834.
26. Wan, X. S., Xu, Y. A., Ware, J. H., Kennedy, A. R., Three immunoassays based on monoclonal antibodies specific for prostate specific antigen (PSA), α-1-antichymotrypsin (ACT), and the PSA-ACT complex. Prostate 2003, 56, 131-141.
27. Saika, T., Tsushima, T., Nasu, Y., Kusaka, N. et al., Prostate specific antigen complexed to α-1-antichymotrypsin in patients with intermediate prostate specific antigen levels. Cancer 2002, 94, 1685-1691.
28. Brandt, B., Griwatz, C., Brinkmann, O., Zänker, K. S., Circulating prostate-specific antigen/CD14-double-positive cells: a biomarker indicating low risk for hematogeneous metastasis of prostate cancer. J. Natl. Cancer Inst. 1997, 89, 174.